This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rosetta Genomics Names Brian Markison Board Chairman

PHILADELPHIA and REHOVOT, Israel, April 12, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG) today announced that the Company's Board of Directors has appointed Director Brian A. Markison, former Chairman and Chief Executive Officer of King Pharmaceuticals, as Rosetta's new Board Chairman, as current chairman, Yoav Z. Chelouche, has resigned from the Company's Board and from his role as its Chairman effective today. Mr. Chelouche continues to serve as the Chairman of Rosetta Green (TASE: RSTG), the Company's majority held subsidiary.  Following these changes, the Company's Board of Directors now has seven members.

"This is an exciting time to be joining Rosetta Genomics as advances in molecularly-targeted therapies in oncology are driving the need for more accurate sub-classification of tumor types, which helps to guide treatment decisions, monitor therapy, predict outcomes and more.  Rosetta's microRNA technologies, with their high reproducibility, robustness and accuracy are ideally suited to accurately provide this valuable clinical information," commented Mr. Markison.  "I look forward to working with management to guide the successful implementation of the Company's commercial strategy and expect the coming 18 months to be transformational as Rosetta Genomics transitions into a fully integrated entity with a growing U.S. commercial oncology presence."

"We thank Yoav for his years of valuable service to Rosetta Genomics.  His contributions were instrumental in guiding the Company through the early clinical development of our pipeline of microRNA diagnostics and biomarkers," commented Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.  "We welcome Brian as our new Chairman and look forward to utilizing his extensive industry expertise, particularly as we implement our domestic commercial plan in oncology.  As the former Chairman and CEO of a successful, large U.S. biopharmaceutical company, Brian's considerable experience will be instrumental in guiding Rosetta as we build our commercial capabilities and continue to transition into a leading molecular diagnostics company," added Mr. Berlin.

About Rosetta Genomics

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company's microRNA-based tests, miRview™ squamous, miRview™ mets, miRview™ mets2 and miRview™ meso, are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the growth of the Company's U.S. commercial oncology presence constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2010 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

SOURCE Rosetta Genomics, Ltd.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs